

## California COVID-19 Vaccination Program Update

Weekly Wrap Up – June 3, 2022

### Pediatric Preordering Reminders

Wave 1 of pediatric pre-ordering for both Pfizer (Ages 6 months – 4 years) and Moderna (Ages 6 months – 5 years) started today, June 3. The minimum order amount is 100 doses for both products. Wave 1 orders will be open through 5PM on Monday, June 6, during which both Providers and LHDs/MCEs can place pre-orders for their locations. Any order placed after that time will be a part of Wave 2 taking place from Tuesday, June 7 until Friday, June 10 at 5PM.

Pending FDA, CDC, and Western States approvals, Wave 1 deliveries will take place on Monday, June 20 (Federal Juneteenth Holiday). If you cannot receive product this day, please order during Wave 2. Wave 2 deliveries will take place June 21 through June 24.

Routine ordering for the new products and the small orders timeline (Pfizer only through the TPR (AmerisourceBergen)) will be shared once we receive more information. The regular order cadence will continue for existing approved COVID-19 vaccine products.

Please see the calendar below for any questions regarding the pre-order timing.

#### New Pediatric COVID-19 Vaccine (Pfizer: Ages 6 Months–4 Years, Moderna: Ages 6 Months–5 Years) Pre-Ordering Week Cadence

Monday	Tuesday	Wednesday	Thursday	Friday
		June 1	2	3 Wave 1 Pre-Orders Opens on myCAvax (Delivery on 6/20) <sup>†</sup>
6 Wave 1 Order by 5pm (Delivery on 6/20) <sup>†</sup>	7 LHD Approval by 12pm CDPH submits orders–Wave 1	8	9	10 Wave 2 Order by 5pm (Delivery on 6/21-6/24)
13 LHD Approval by 12pm CDPH submits orders–Wave 2	14 FDA VRBPAC	15 FDA VRBPAC (anticipated approval <sup>^</sup> )	16	17-18 ACIP Western States (anticipated approval <sup>^</sup> )
20 Juneteenth Holiday Wave 1 Deliveries (contingent upon approval <sup>^</sup> )	21 Wave 2 Deliveries (contingent upon approval <sup>^</sup> )	22	23	24

<sup>†</sup> Only order during Wave 1 if you can receive vaccines on Monday, June 20<sup>th</sup>, otherwise order during Wave 2.

<sup>\*\*</sup> Pre-orders submitted after 6/6 at 5pm will be included in Wave 2.

<sup>^</sup> Delivery is contingent upon FDA, ACIP, and Western States approval

---

## Provider FAQ of the Week

***Q: Where can COVID-19 vaccine Providers find clinical talking points for recommending COVID-19 vaccines for children?***

A: The following are clinical talking points for COVID-19 vaccine Providers to reference when recommending COVID-19 vaccines for children:

- During the Omicron period, unvaccinated children ages 5-11 were [twice as likely](#) to be hospitalized with COVID-19 than vaccinated children.
- During the Omicron period, [1 in 5 children](#) hospitalized with COVID-19 required ICU-level care. Vaccination [lowered the risk of critical COVID-19 by 79%](#).
- [Children with pre-existing conditions](#) are at higher risk for severe COVID-19 outcomes. Vaccination is especially recommended to keep children with chronic conditions and disabilities safe and healthy.
- Healthy children with no pre-existing conditions can have severe COVID-19, too. In fact, [almost half](#) of children younger than 18 years hospitalized with COVID-19 have no underlying conditions.
- During the Omicron period, [63% of children under 5 years](#) and [30% of children 5-11 years](#) hospitalized with COVID-19 did not have any underlying conditions.
- The vaccine does not protect against all COVID-19 infection, but [multiple studies](#) have shown it is effective in preventing severe illness and hospitalization, [including against the Omicron variant](#).

For a full list of clinical talking points for recommending COVID-19 vaccination for children, please visit this [job aid](#). Please also watch the Talking with Parents about COVID-19 Vaccines for Children webinar [recording](#) and view [slides](#).

[California COVID-19 Vaccination Program Provider FAQs](#), updated weekly

---

## Clinical Guidance Update: People with Current SARS-CoV-2 Infection

Vaccination following SARS-CoV-2 infection further increases protection from subsequent infection and hospitalization, including in the the setting of increased circulation of more infectious SARS-CoV-2 strains.

People who recently had SARS-CoV-2 infection may consider delaying a primary series dose or their first or second COVID-19 vaccine booster dose by 3 months from symptom onset or positive test (if the infection was asymptomatic).

- Increased time between infection and vaccination may result in an improved immune response to vaccination.
- Low risk of reinfection has been observed in the weeks to months following infection.
- Consider risk of COVID-19 severe disease, COVID-19 community level, or characteristics of predominant SARS-CoV-2 strain when determining whether or not to delay COVID-19 vaccination after infection.

Please see [CDC Interim Clinical Considerations for use of COVID-19 Vaccines: COVID-19 Vaccination and SARS-CoV-2 Infection](#) for detailed information.

---

## Reporting Doses Spoiled, Expired, or Wasted

Vaccine wastage is [expected and may be unavoidable](#). California COVID-19 Vaccination Program providers must document and track vaccine wastage as part of routine vaccine inventory management activities and report the number of doses of COVID-19 vaccine that was unused, spoiled, expired, or wasted as required.

Please see the [Reporting Doses Spoiled, Expired, or Wasted](#) job aid for complete guidance.

---

## Pfizer Training Sessions

Please attend one of the following training sessions:

- [Tuesday, June 7 at 12PM](#) | Password: tYsMeySr623
- [Wednesday, June 8 at 9AM](#) | Password: nGmBpsdV872
- [Thursday, June 9 at 9AM](#) | Password: fMpj7u8u9F4

To access all sessions, please visit [Pfizer Medical Updates and Training](#).

---

## Useful Resources

- [COVID-19 Vaccine Timing by Age Chart in English | Spanish](#)
- [COVID-19 Vaccine Product Guide](#)
- [Long COVID Fact Sheet](#)
- [Risk Comparison in Youth Fact Sheet](#)
- [Risk Comparison in Teens Fact Sheet](#)
- [Toolkit for Providers of Pediatric Services](#)
- [COVID 19, Myocarditis, and Vaccines Fact Sheet](#)
- [Requesting COVID-19 Vaccination Staff](#)

---

## Support Opportunities

### Provider Office Hours

Please attend our weekly webinars to hear updates from the COVID-19 Vaccination Program and have your questions answered.

- [Fridays 9–10 AM](#)
- [Archived Sessions](#) | [Provider FAQs](#)

### My Turn & myCAvax Office Hours for LHDs and Providers

- [Every Monday at 12:00 PM](#)

### COVID Call Center for Providers

- For Program information: email [covidcallcenter@cdph.ca.gov](mailto:covidcallcenter@cdph.ca.gov) or call (833) 502-1245 (Monday – Friday, 8AM–6PM)

### myCAvax Help Desk

- For technical issues (password resets, etc.): email [myCAvax.HD@accenture.com](mailto:myCAvax.HD@accenture.com) or call (833) 502-1245, option 3 (Monday – Friday 8AM – 6PM)

- System related training materials are available via the Knowledge Center in myCAvax and at [EZIZ.org/COVID](https://EZIZ.org/COVID)

## My Turn Help Desk

- Onboarding: email [myturnonboarding@cdph.ca.gov](mailto:myturnonboarding@cdph.ca.gov) Technical support for My Turn Clinic: email [MyTurn.Clinic.HD@Accenture.com](mailto:MyTurn.Clinic.HD@Accenture.com) or call (833) 502-1245, option 4 (Monday – Friday 8AM – 6PM).
- [Job aids, demos and training opportunities](#)

[View Archived](#)



**Vaccinate ALL 58**

Together we can end the pandemic.

COVID19 Vaccination Program



California Dept of Public | Immunization Branch  
850 Marina Bay Pkwy  
Richmond CA 94804  
[View In Browser](#)

Copyright @Microsoft Dynamics, All right reserved.  
850 Marina Bay Parkway, Bldg P Richmond CA 94804  
[Unsubscribe](#)